» Articles » PMID: 37526080

Regulation of Antigen-specific T Cell Infiltration and Spatial Architecture in Multiple Myeloma and Premalignancy

Abstract

Entry of antigen-specific T cells into human tumors is critical for immunotherapy, but the underlying mechanisms are poorly understood. Here, we combined high-dimensional spatial analyses with in vitro and in vivo modeling to study the mechanisms underlying immune infiltration in human multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS). Clustered tumor growth was a feature of MM but not MGUS biopsies, and this growth pattern was reproduced in humanized mouse models. MM biopsies exhibited intralesional as well as spatial heterogeneity, with coexistence of T cell-rich and T cell-sparse regions and the presence of areas of T cell exclusion. In vitro studies demonstrated that T cell entry into MM clusters was regulated by agonistic signals and CD2-CD58 interactions. Upon adoptive transfer, antigen-specific T cells localized to the tumor site but required in situ DC-mediated antigen presentation for tumor entry. C-type lectin domain family 9 member A-positive (CLEC9A+) DCs appeared to mark portals of entry for gradients of T cell infiltration in MM biopsies, and their proximity to T cell factor 1-positive (TCF1+) T cells correlated with disease state and risk status. These data illustrate a role for tumor-associated DCs and in situ activation in promoting the infiltration of antigen-specific T cells in MM and provide insights into spatial alterations in tumor/immune cells with malignant evolution.

Citing Articles

Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.

Hussain Z, Zhang Y, Qiu L, Gou S, Liu K NPJ Vaccines. 2025; 10(1):27.

PMID: 39920156 PMC: 11806010. DOI: 10.1038/s41541-025-01084-2.


Topological importance of CD8 T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma.

Takahashi H, Ito S, Nakanishi Y, Miura K, Nishimaki H, Nakagawa M Ann Hematol. 2025; .

PMID: 39820429 DOI: 10.1007/s00277-025-06189-1.


Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis.

Qureshi Z, Jamil A, Altaf F, Siddique R, Ahmed F Ann Hematol. 2024; 103(12):4901-4912.

PMID: 39511034 DOI: 10.1007/s00277-024-06078-z.


Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.

Jo Y, Sim H, Yun B, Park Y, Jin H Exp Mol Med. 2024; 56(10):2113-2126.

PMID: 39349829 PMC: 11541569. DOI: 10.1038/s12276-024-01317-9.


Understanding CAR-T therapy in myeloma: 1 cell at a time.

Dhodapkar M Blood Adv. 2024; 8(13):3560-3561.

PMID: 38980672 PMC: 11319829. DOI: 10.1182/bloodadvances.2024013292.


References
1.
Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

2.
Dhodapkar M, Krasovsky J, Olson K . T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A. 2002; 99(20):13009-13. PMC: 130577. DOI: 10.1073/pnas.202491499. View

3.
Anandappa A, Wu C, Ott P . Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discov. 2020; 10(2):185-197. PMC: 7007384. DOI: 10.1158/2159-8290.CD-19-0790. View

4.
Dhodapkar M, Krasovsky J, Osman K, Geller M . Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003; 198(11):1753-7. PMC: 2194131. DOI: 10.1084/jem.20031030. View

5.
Gomes A, Hara T, Lim V, Herndler-Brandstetter D, Nevius E, Sugiyama T . Hematopoietic Stem Cell Niches Produce Lineage-Instructive Signals to Control Multipotent Progenitor Differentiation. Immunity. 2016; 45(6):1219-1231. PMC: 5538583. DOI: 10.1016/j.immuni.2016.11.004. View